Key Highlights

  • Vanda Pharmaceuticals secured Orphan Drug status from the European Commission for imsidolimab.
  • The designation covers generalized pustular psoriasis.
  • Orphan drug status provides key regulatory and market incentives in the EU.
  • The company awaits an FDA decision on its BLA, with a PDUFA date set for December 12, 2026.

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) secured orphan drug status from the European Commission for imsidolimab in generalized pustular psoriasis, a designation providing key regulatory and market incentives in the EU.

What Happened

Meanwhile, the company awaits an FDA decision on its BLA with a PDUFA date set for December 12, 2026.

Market Reaction

The disclosed information does not include stock price or trading data for Vanda Pharmaceuticals following the orphan drug designation.

Outlook

The FDA's decision on the imsidolimab BLA, with a PDUFA date of December 12, 2026, represents the next major disclosed regulatory milestone for Vanda Pharmaceuticals.